
    
      This is a single center, single arm phase II clinical research, to evaluate the self D - CIK
      cells to treat liver cancer, renal clear cell carcinoma, nasopharyngeal carcinoma, lung
      cancer, colorectal cancer, breast cancer patient safety and efficacy of plan participants
      included 1372 cases of the subjects, experimental group 686 cases, control group 686 cases,
      control group adopts the liver, renal clear cell carcinoma, nasopharyngeal carcinoma, lung
      cancer, colorectal cancer, breast cancer patients after conventional treatment (surgery,
      chemotherapy and radiotherapy) did not receive D - CIK cell therapy of external control
    
  